KRAS and neoplasm: And high expression of eIF3E and eIF3J was observed more in patients with residual tumours (13/4 vs. 172/170, p = 0.0456) and without mutations in KRAS/EGFR/ALK (47/48 vs. 86/46, p = 0.0206), respectively.